[go: up one dir, main page]

WO2008011478A3 - Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds - Google Patents

Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds Download PDF

Info

Publication number
WO2008011478A3
WO2008011478A3 PCT/US2007/073806 US2007073806W WO2008011478A3 WO 2008011478 A3 WO2008011478 A3 WO 2008011478A3 US 2007073806 W US2007073806 W US 2007073806W WO 2008011478 A3 WO2008011478 A3 WO 2008011478A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
amino
propionic acid
acid amides
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/073806
Other languages
French (fr)
Other versions
WO2008011478A2 (en
Inventor
John E Donello
Fabien J Schweighoffer
Bertrand Leblond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of WO2008011478A2 publication Critical patent/WO2008011478A2/en
Publication of WO2008011478A3 publication Critical patent/WO2008011478A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed herein are methods of treating a patient suffering from one or more types of chronic pain using compounds of Formula 1 wherein the variables have the meaning disclosed in the specification.
PCT/US2007/073806 2006-07-19 2007-07-18 Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds Ceased WO2008011478A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80779206P 2006-07-19 2006-07-19
US60/807,792 2006-07-19

Publications (2)

Publication Number Publication Date
WO2008011478A2 WO2008011478A2 (en) 2008-01-24
WO2008011478A3 true WO2008011478A3 (en) 2008-03-20

Family

ID=38793589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073806 Ceased WO2008011478A2 (en) 2006-07-19 2007-07-18 Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds

Country Status (1)

Country Link
WO (1) WO2008011478A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519840A (en) 2004-11-10 2008-06-12 ジェンザイム・コーポレイション How to treat diabetes
ES2546181T3 (en) 2006-05-09 2015-09-21 Genzyme Corporation Methods of treating fatty liver disease by inhibiting the synthesis of glycosphingolipids
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
BRPI0823522A2 (en) 2007-10-05 2014-01-07 Genzyme Corp USE OF CERAMIDE DERIVATIVE COMPOUND
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
AU2010295703A1 (en) 2009-09-16 2012-04-12 Allergan, Inc. Compositions and methods for treating seizure disorders
US20110065748A1 (en) * 2009-09-16 2011-03-17 Allergan, Inc. Compositions and methods for treating disorders of gastrointestinal motility
CA2774355A1 (en) 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating spasticity
SI3033327T1 (en) * 2013-08-15 2018-05-31 Allergan, Inc. (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016786A1 (en) * 1993-12-17 1995-06-22 Dsm N.V. Phenylserine amides and the preparation of phenylserines/phenylserine amides
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
WO2006081252A2 (en) * 2005-01-26 2006-08-03 Allergan, Inc. Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016786A1 (en) * 1993-12-17 1995-06-22 Dsm N.V. Phenylserine amides and the preparation of phenylserines/phenylserine amides
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US20030153768A1 (en) * 2001-11-26 2003-08-14 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
WO2006081252A2 (en) * 2005-01-26 2006-08-03 Allergan, Inc. Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
WO2006081273A1 (en) * 2005-01-26 2006-08-03 Allergan, Inc. 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
WO2006081280A1 (en) * 2005-01-26 2006-08-03 Allergan, Inc. 3-heterocyclyl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIXLER R L ET AL: "Synthesis of beta-/4-pyridyl)-DL-analine and of beta-/4-pyridyl-1-oxide)-DL-, D-, and L-analine", JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 23, April 1958 (1958-04-01), pages 575 - 584, XP002380699, ISSN: 0022-3263 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KASTRON, YA. A. ET AL: "Reaction of ethyl .beta.-furylglycidate with ammonia", XP002462452, retrieved from STN Database accession no. 1966:19065 *
LATVIJAS PSR ZINATNU AKADEMIJAS VESTIS, KIMIJAS SERIJA , (4), 471-7 CODEN: LZAKAM; ISSN: 0002-3248, 1965 *
THE MERCK DIVISISION: "The Merk Index", 2001, MERCK, XP002462479 *

Also Published As

Publication number Publication date
WO2008011478A2 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
WO2008011478A3 (en) Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
WO2005086661A3 (en) Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2007134678A3 (en) Triazole derivatives ii
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2010093849A3 (en) Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007014278A3 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
WO2008036144A3 (en) Nanoshells on polymers
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2007089715A3 (en) Method for treatment of neuropathic pain
HUE059861T2 (en) N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
WO2009010139A3 (en) Quinazolinamide derivatives
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
WO2008011483A3 (en) Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005044200A3 (en) Methods and compositions for treating mcp-1 related pathologies
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07840433

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07840433

Country of ref document: EP

Kind code of ref document: A2